Product Description
to Treat Alzheimer's Disease Type Dementia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02185053)
Mechanisms of Action: ACHE Inhibitor,M3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PET Study | P2 |
Withdrawn |
Alzheimer Disease |
2017-06-30 |
|
| CPC-001-10 | P2 |
Completed |
Alzheimer Disease |
2016-10-18 |
|
| CPC-001-07 | P2 |
Completed |
Alzheimer Disease |
2016-07-31 |